Compare Incyte Corporation (INCY) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Banco Santander SA — how do they compare? Incyte Corporation trades at $117.9 (market cap $23.11B), while Banco Santander SA trades at $13.7 (market cap $191.46B). The key difference: Banco Santander SA is far larger — about 8.3× Incyte Corporation's market cap, and Banco Santander SA pays a 2.09% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SAN | |
|---|---|---|
Market Cap | $23.11B | $191.46B |
Sector | Health | Financials |
52-Week High | $118.52 | $14.37 |
52-Week Low | $67.38 | $8.40 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Banco Santander (SAN) trades at $13.31, down 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.41, beating expectations, but missed in prior quarters. Revenue for 2025 was $60.02B with a net income margin of 26.72%. Recent news highlights Santander's AI initiatives, acquisition of Webster Bank, and becoming Spain's most valuable company. Cash flow trends show operational challenges, with net cash flow negative in recent years.
Outlook is cautiously optimistic with a 64% analyst buy rating, targeting efficiency gains and AI-driven value. Risks include regulatory probes, declining cash flows, and high debt levels. The stock offers a dividend yield with the recent $0.15 payout, but investors should weigh operational improvements against financial volatility and macroeconomic pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
